US Stock MarketDetailed Quotes
LEXX Lexaria Bioscience
- 3.0100
- +0.0800+2.73%
Trading Jun 18 11:19 ET
43.11MMarket Cap-4492P/E (TTM)
3.1000High2.8900Low74.98KVolume2.9200Open2.9300Pre Close224.66KTurnover0.62%Turnover RatioLossP/E (Static)14.32MShares6.850052wk High6.62P/B36.72MFloat Cap0.705152wk Low--Dividend TTM12.20MShs Float12.5000Historical High--Div YieldTTM7.17%Amplitude0.6488Historical Low2.9960Avg Price1Lot Size
Lexaria Bioscience Stock Forum
Sign in to post a comment
$Lexaria Bioscience(LEXX.US$ Lexaria Bioscience Corp: Expects to Complete Third (Final) Arm of Study in Early July
2
3
$Lexaria Bioscience(LEXX.US$
NEWS
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
Lexaria Bioscience has awarded a contract for its third human pilot study to a contract research organization. This study will evaluate the dual action glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) using a DehydraTECH-processed tirzepatide in an oral capsule format versus the injected tirzepatide (Zepbound® by Eli Lilly). The study aims to determine the absorption, hu...
NEWS
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
Lexaria Bioscience has awarded a contract for its third human pilot study to a contract research organization. This study will evaluate the dual action glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) using a DehydraTECH-processed tirzepatide in an oral capsule format versus the injected tirzepatide (Zepbound® by Eli Lilly). The study aims to determine the absorption, hu...
$Lexaria Bioscience(LEXX.US$
NEWS
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
Lexaria Bioscience has announced the receipt of two new US patents in the medical fields of hypertension and epilepsy. The first patent, part of Lexaria's patent family #21, focuses on compositions and methods for treating hypertension using DehydraTECH-processed cannabidiol (CBD). The second patent, part of patent family #24, pertains to treating epilepsy, highlighting DehydraTECH-...
NEWS
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
Lexaria Bioscience has announced the receipt of two new US patents in the medical fields of hypertension and epilepsy. The first patent, part of Lexaria's patent family #21, focuses on compositions and methods for treating hypertension using DehydraTECH-processed cannabidiol (CBD). The second patent, part of patent family #24, pertains to treating epilepsy, highlighting DehydraTECH-...
$Lexaria Bioscience(LEXX.US$ Reuters· 3 mins ago
Lexaria Bioscience: Human Pilot Study #2, GLP-1-H24-2 Underway & First Dosing Visit for All Nine Study Participants Has Already Concluded
Lexaria Bioscience: Human Pilot Study #2, GLP-1-H24-2 Underway & First Dosing Visit for All Nine Study Participants Has Already Concluded
2
$Lexaria Bioscience(LEXX.US$
NEWS
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
NEWS
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
$Lexaria Bioscience(LEXX.US$
Company AnnouncementsLexaria Bioscience Showcases Drug Delivery Breakthrough
Lexaria Bioscience Corp. (LEXX) has released an update. Lexaria Bioscience Corp., a leader in drug delivery platforms, will present its latest advancements in improving GLP-1 drugs using its DehydraTECH technology at the 14th Annual LD Micro Invitational in New York. CEO Chris Bunka is set to discuss recent discoveries and forthcoming studies that could significantly impact...
Company AnnouncementsLexaria Bioscience Showcases Drug Delivery Breakthrough
Lexaria Bioscience Corp. (LEXX) has released an update. Lexaria Bioscience Corp., a leader in drug delivery platforms, will present its latest advancements in improving GLP-1 drugs using its DehydraTECH technology at the 14th Annual LD Micro Invitational in New York. CEO Chris Bunka is set to discuss recent discoveries and forthcoming studies that could significantly impact...
1
$Lexaria Bioscience(LEXX.US$ Lexaria To Begin Diabetes And Weight Loss Animal Study WEIGHT-A24-1
Benzinga· 4 mins ago
Benzinga· 4 mins ago
1
$Lexaria Bioscience(LEXX.US$ glp is like AI.. everyone's chasing the problem with bioscience biotech to go from phase one phase two phase 3 human trials final most companies never make it that far it's a series of disappointments by the time it ever gets approved Lily will be a 2 trillion dollar company
$Lexaria Bioscience(LEXX.US$ Something dont add up?
6
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Stock_Drift : Duly noted
PYUN970IHaveChosen :
TTSAB! (lol) not sure where the previous post came from! Not here….
TrytosaveabitOP PYUN970IHaveChosen: You’re welcome